Loading data for XLO — first visit, this takes a few seconds.

アラート

Xilio Therapeutics Inc. (XLO)

NasdaqCM: XLO · リアルタイム株価 · USD

9.23

+0.00 (0.00%)

終値時点： Aug 21, 2026, 12:00 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

0.00% (1D)

買気配	6.56
時価総額	60.73M
売上高（TTM）	64.09M
純利益（TTM）	-21.83M
	-0.12
	-0.31
	n/a
	-15.91
PBR（TTM）	1.19
PSR（TTM）	0.95
決算発表日	n/a

売気配	11.62
出来高	5,119
平均出来高（20日）	34,575
始値	9.21
前日終値	9.23
当日レンジ	9.11 - 9.23
52週レンジ	6.47 - 12.74
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

XLOについて

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activ...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Oct 22, 2021

従業員数 76

上場取引所 NasdaqCM

ティッカー XLO

ウェブサイト https://xiliotx.com

企業情報の全文

業績

2025年のXilio Therapeuticsの売上高は43.77Mで、前年の6.34Mから589.88%の増加でした。利益は-35.04Mで、-39.84%の減少でした。

財務諸表

決算サプライズ

Xilio TherapeuticsはAug 12, 2026に四半期決算を発表しました：

売上高は $12.65M で、予想を下回りました $0, うち 331.67% の前年比増加にあたります.
EPSは -0.33 で、予想を上回りました 0.26, うち 88.21% の前年比増加にあたります.

ニュース

4週間前 · Simply Wall St.

3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership

Most small-cap biotech stocks are pure clinical bets. These three already have revenue on the books and insiders backing them with their own capital.

3か月前 · Zacks

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of +12.12% and +48.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

3か月前 · Zacks

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

3か月前 · Zacks

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -27.71% and -17.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

4か月前 · Zacks

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2ページ中1ページ

Xilio Therapeutics Inc. (XLO)